[2] In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

[4] AC Immune was founded in 2003 by current CEO Andrea Pfeifer, Ph.D.[5] and funded primarily by German billionaire Dietmar Hopp.

[8] To develop crenezumab, AC Immune utilized its SupraAntigen technology, which involves injecting mice with liposomes that contain several hundred peptide mimics of antigens in order to generate a multitude of antibodies, from which the ones with best specificity are selected.

[9] It is believed that crenezumab works by causing beta amyloid proteins to transition from an insoluble to a soluble form,[10] inhibiting aggregation and promoting disaggregation of existing plaques.

[16] In June, the NIH announced the preliminary results stating that crenezumab failed to give "clinical benefit in cognitively healthy people who have a rare genetic mutation that causes early-onset Autosomal Dominant Alzheimer's Disease (ADAD).

"[3] The Banner Alzheimer’s Institute also concurred, as the executive director Eric Reiman said, "We’re disappointed that crenezumab did not show a significant clinical benefit.